Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24205329 | 0.91 | TSHR (0.55) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26034446 | 0.91 | TSHR (0.47) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205096 | 0.91 | TSHR (0.47) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205119 | 0.88 | TSHR (0.45) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26034508 | 0.86 | TSHR (0.47) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26034448 | 0.84 | TSHR (0.45) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26034705 | 0.82 | THRB (0.34) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205116 | 0.81 | TSHR (0.47) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205094 | 0.81 | TSHR (0.45) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26034449 | 0.81 | TSHR (0.45) | TSHRPOLBAPEX1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4182736-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-05-24 | — | — | EP | disclosed |
| EP-4182737-A1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6D, PDE6A | TSHR 4585/4885POLB 1579/4885APEX1 147/4885 |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | TSHR 4592/4885POLB 1376/4885APEX1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.